PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO pep… Read more
PepGen Ltd (PEPG) - Total Liabilities
Latest total liabilities as of December 2025: $26.46 Million USD
Based on the latest financial reports, PepGen Ltd (PEPG) has total liabilities worth $26.46 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PepGen Ltd - Total Liabilities Trend (2019–2025)
This chart illustrates how PepGen Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PepGen Ltd Competitors by Total Liabilities
The table below lists competitors of PepGen Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Dongzhu Landscape Co
SHG:603359
|
China | CN¥4.04 Billion |
|
FAWER Automotive Parts Ltd Co
SHE:200030
|
China | HK$8.51 Billion |
|
Ensari Deri Gida Sanayi ve Ticaret AS
IS:ENSRI
|
Turkey | TL770.87 Million |
|
Doright Co.Ltd.
SHE:300950
|
China | CN¥445.21 Million |
|
Xuancheng Valin Precision Technology Co Ltd
SHG:603356
|
China | CN¥884.37 Million |
|
Gujarat Ambuja Exports Limited
NSE:GAEL
|
India | ₹6.81 Billion |
|
Kailong High Technology Co. Ltd.
SHE:300912
|
China | CN¥763.42 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down PepGen Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PepGen Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PepGen Ltd (2019–2025)
The table below shows the annual total liabilities of PepGen Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $26.46 Million | -17.98% |
| 2024-12-31 | $32.26 Million | -6.84% |
| 2023-12-31 | $34.63 Million | -8.41% |
| 2022-12-31 | $37.81 Million | +258.48% |
| 2021-12-31 | $10.55 Million | +1115.09% |
| 2020-12-31 | $868.00K | +166.26% |
| 2019-12-31 | $326.00K | -- |